Subarachnoid hemorrhage is a type of stroke caused by bleeding into the space between the protective membranes surrounding the brain. This type of hemorrhagic stroke represents a neurological emergency, which is why patients with this type of stroke require immediate intensive care. When the brain’s normal blood supply is disrupted due to an acute blockage rather than a brain bleed, this is called an ischemic stroke. However, an ischemic stroke can also occur as the result of a subarachnoid hemorrhage. More than half of all patients who have had a severe subarachnoid hemorrhage will develop an ischemic stroke within the first two weeks after their brain bleed.

Researchers from Charité – Universitätsmedizin Berlin (Berlin, Germany) have shown that massive electrochemical waves in the brain act as a marker announcing an impending ischemic stroke. Electrodiagnostic monitoring of these waves enables clinicians to identify the signs of an impending stroke early, particularly in comatose patients receiving intensive care following a subarachnoid hemorrhage. The findings could serve as the basis for the development of new treatments. Charité researchers have identified a biomarker which indicates that a patient is at high risk of an impending stroke post-subarachnoid hemorrhage.

The discovery was based on a phenomenon known as ‘spreading depolarizations’, massive waves of electrochemical energy release caused by the toxic by-products of blood breakdown following hemorrhagic stroke. Affected areas of the brain require large amounts of energy in order to restore normal conditions. In a healthy brain, very brief periods of depolarization (a change in the membrane potential) of nerve cells are normal and linked to blood supply: the brain can widen blood vessels as required, thereby balancing increased energy needs with an increase in blood flow. After a subarachnoid hemorrhage, however, pathologically massive and long-lasting spreading depolarizations can disrupt signaling cascades between nerve cells and blood vessels, so that the depolarization of nerve cells triggers extreme blood vessel constriction. This, in turn, deprives the nerve cells of energy, rendering them incapable of restoring normal electrochemical gradients. If depolarization persists for too long, these nerve cells will begin to die off.

This was the starting point of the current clinical study, which was conducted across five different university hospitals. In order to take accurate measurements of spreading depolarizations, the researchers employed electrocorticography, a procedure used to measure brain activity in neurological intensive care patients. To enable these types of measurements, patients admitted with subarachnoid hemorrhage had electrodes implanted under the dura mater (the brain’s tough outer membrane). The researchers also used imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT), analyzing approximately 1,000 brain scans from 180 patients with subarachnoid hemorrhage. The largest clinical study on spreading depolarizations to date revealed that the average patient loses 46 milliliters of brain tissue during the early phase after their brain bleed, i.e., by the time they reach hospital. The average patient then loses a further 36 milliliters of brain tissue during the first two weeks after their hemorrhage, i.e., while in intensive care.

This approach follows the principles of precision medicine, which aims to tailor treatments to the needs of the individual patient. The researchers plan to test spreading depolarization monitoring as an early warning system for use in routine clinical practice, where they hope it will help to improve treatment options for people with stroke. Artificial intelligence-based methods are likely to play a major role in this regard. The automated analysis of electrodiagnostic data will be necessary to ensure intensive care physicians are notified in real time when an unconscious patient’s brain tissue is at risk of further damage.

“It is difficult to judge when a new stroke might be developing, especially in patients who are in a coma and hence unable to tell us anything about their health status,” explained first author Prof. Dr. Jens Dreier of Charité’s Center for Stroke Research. “In our study, we have shown that electrodiagnostic monitoring makes this moment visible. This means that treatment can be started in time, even in comatose patients, before it is too late.”

http://www.gzjiayumed.com/en/index.asp